COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients-A Single Institution Observational Cohort

Article Sidebar

PDF Download
Published Jul 29, 2023
DOI: https://doi.org/10.18103/mra.v11i7.2.4177

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Jan S. Moreb
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC
Amanda Edwards
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC
Savannah Perry
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC
James Dugan
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC
Raymond Thertulien
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Charlotte, NC
Kathleen Elliott
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC
Alan P Skarbnik
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Charlotte, NC
Kimberly Ward
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, NC
Abhishek R. Chilkulwar
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Charlotte, NC
Patricia L Kropf
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Charlotte, NC
Franklin Chen
Hematology, Transplantation and Cellular Therapy, Novant Health Cancer Institute, Winston Salem, NC

Abstract

COVID 19 infection had significant impact, including high mortality rate, in immunosuppressed patients including patients with hematological malignancies undergoing hematopoietic stem cell transplantation. This retrospective study describes the characteristics and outcomes of COVID 19 infection in autologous stem cell transplantation (ASCT) recipients. The time period for the study was Feb 2020 to Feb 2022. During that time 29 patients (28%) out of 102 ASCT recipients became infected with COVID 19 diagnosed by PCR test. 22 and 7 were multiple myeloma (MM) and lymphoma (Ly) patients, respectively.  Infection rate was 30.5% among MM patients and 23% among Ly patients. Median age was 59 years, 16 were females, 45% were Caucasians. Eight patients had infection prior to first ASCT, and one prior to second ASCT. Nine developed the infection within 12 months post ASCT. 6 patients had 2nd episode of infection within 8-20 months from 1st episode, only one patient required hospitalization. One MM patient contracted the infection from his relatives while in the hospital undergoing ASCT. He was one of total of 3 deaths from COVID infection. All 3 patients had significant comorbidities including 2 on dialysis and the 3rd had chronic kidney failure stage 3B, all were MM patients within < 1 year from ASCT. Two of them were vaccinated with the primary shots but no boosters. Overall, 8 patients were hospitalized due to COVID infection, 7 had multiple comorbidities and 6 had low absolute lymphocyte counts (ALC). Sixteen patients were noted to have low ALC around the time of infection, 5 were Ly patients. Seven patients had no symptoms, only 3 of them were vaccinated. Overall, 12 were vaccinated at the time of infection. 10 patients received monoclonal antibodies after they became positive for COVID. Evusheld was given to 2 patients. Other treatments used mainly in hospitalized patients include dexamethasone, remdesivir, and fresh frozen plasma. In conclusion, our patient population seems to have done better than published reports with about 10% mortality from COVID infection. Comorbidities, especially advanced renal failure, and low ALC may have contributed to worse morbidity and mortality outcomes.

Article Details

How to Cite
MOREB, Jan S. et al. COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients-A Single Institution Observational Cohort. Medical Research Archives, [S.l.], v. 11, n. 7.2, july 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4177>. Date accessed: 22 dec. 2024. doi: https://doi.org/10.18103/mra.v11i7.2.4177.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 7.2 (2023): July Issue, Vol.11, Issue 7.2
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193.
2. Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885-2894.
3. Lim YJ, Khan U, Karpha I, et al. COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis. E J Haem. 2022;3(3):862-872.
4. Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656-6667.
5. Daudt LE, Corso MCM, Kerbauy MN, et al. COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO). Bone Marrow Transplant. 2022;57(3):453-459.
6. Busca A, Salmanton-García J, Marchesi F, et al. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Front Immunol. 2023 Feb 24;14:1125030. Doi: 10.3389/fimmu.2023.1125030.
7. Altuntas F, Ata N, Yigenoglu TN, et al. Turkish Ministry of Health, Hematology Scientific Working Group. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021;56(4):952-955.
8. Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2022 Apr;24(2):e13792. doi: 10.1111/tid.13792.
9. Callaway E. COVID's future: mini-waves rather than seasonal surges. Nature. 2023; 617(7960):229-230.
10. Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first and second COVID-19 waves in the Bronx, New York: A retrospective cohort study. Lancet Reg Health Am. 2021 Nov;3:100041. doi: 10.1016/j.lana.2021.100041.
11. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2021;21(5):1825-1837.
12. Waghmare A, Abidi MZ, Boeckh M, et al, Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant. 2020; 26(11):1983-1994.
13. Dioverti V, Boghdadly ZE, Shahid Z, et al. Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplant Cell Ther. 2022;28(12):810-821.
14. Ljungman P, Mikulska M, de la Camara R, et al; European Society for Blood and Marrow Transplantation. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55(11):2071-2076.
15. Letailleur V, Le Bourgeois A, Guillaume T, et al. Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France. JAMA Netw Open. 2022;5:e2247534.
16. Bhatt NS, Sharma A, St Martin A, et al. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022;28:696.e1-696.e7.
17. Knaus HA, Rabitsch W, Buchtele N, Cserna J, Wohlfarth P. Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection. Ann Hematol. 2022; 101(5):1107-1110.
18. Kanellopoulos A, Ahmed MZ, Kishore B, et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. Br J Haematol. 2020;190(2):e67-e70.
19. Malek AE, Adachi JA, Mulanovich VE, et al. Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients. Transpl Infect Dis. 2021;23 (4):e13606. doi: 10.1111/tid.13606.
20. Milczarek S, Baumert B, Sobuś A, et al. COVID-19 during Early Phase of Autologous Stem Cell Transplantation. Medicina (Kaunas). 2021;57(7):724-728.
21. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11(1):5761. doi: 10.1038/s41467-020-19623-x.
22. Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness: A Population-Based Cohort Study. Ann Intern Med. 2021;174(3):308-315.
23. Gutiérrez-Valencia M, Leache L, Librero J, Jericó C, Enguita Germán M, García-Erce JA. ABO blood group and risk of COVID-19 infection and complications: A systematic review and meta-analysis. Transfusion. 2022;62(2):493-505.
24. Deschasaux-Tanguy M, Szabo de Edelenyi F, Druesne-Pecollo N, et al; SAPRIS-SERO study group; de Lamballerie X, Carrat F, Touvier M. ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study. Sci Rep. 2023;13(1):4775. doi: 10.1038/s41598-023-30714-9.
25. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2021;48:100785. doi: 10.1016/j.blre.2020.100785.
26. Jericó C, Zalba-Marcos S, Quintana-Díaz M, et al. Relationship between ABO Blood Group Distribution and COVID-19 Infection in Patients Admitted to the ICU: A Multicenter Observational Spanish Study. J Clin Med. 2022;11(11):3042. doi: 10.3390/jcm11113042.
27. Kim Y, Latz CA, DeCarlo CS, Lee S, Png CYM, Kibrik P, Sung E, Alabi O, Dua A. Relationship between blood type and outcomes following COVID-19 infection. Semin Vasc Surg. 2021;34(3):125-131.